Selective Trial Populations Weigh Against Advisory Panel Support For Lorqess
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee votes 9 to 5 vote against approval of Arena's weight loss drug, troubled that the study populations didn't reflect the real world.
You may also be interested in...
Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Investors in Arena Pharmaceuticals and others angered by an advisory panel vote last September against approving the company's obesity drug Lorqess (lorcaserin) sent 467 complaints to the CDER Ombudsman's Office.
Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Investors in Arena Pharmaceuticals and others angered by an advisory panel vote last September against approving the company's obesity drug Lorqess (lorcaserin) sent 467 complaints to the CDER Ombudsman's Office.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.